Diamyd Medical outlicences Gene to Neurologix for treatment of Parkinson's disease
09-Aug-2006 -
Diamyd Medical AB has entered into a non-exclusive license agreement by which Neurologix, Inc., obtained rights to use the GAD65 molecule in its development of a therapeutic treatment for Parkinson's disease. Terms of the agreement include a license execution payment of US $500,000, annual fees ...
Enzyme
license agreements
Parkinson's disease